MDxHealth (MDXH)
Market Price (7/9/2026): $0.484 | Market Cap: $25.2 MilSector: Health Care | Industry: Life Sciences Tools & Services
MDxHealth (MDXH)
Market Price (7/9/2026): $0.484Market Cap: $25.2 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -87% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. | Weak multi-year price returns2Y Excs Rtn is -114%, 3Y Excs Rtn is -23% | Penny stockMkt Price is 0.5 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -18 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -16% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 245% Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.9% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -134% Key risksMDXH key risks include [1] securing and maintaining adequate reimbursement and payer acceptance for its products, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -87% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics. |
| Weak multi-year price returns2Y Excs Rtn is -114%, 3Y Excs Rtn is -23% |
| Penny stockMkt Price is 0.5 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -18 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -16% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 245% |
| Not cash flow generativeFCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1.9% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -134% |
| Key risksMDXH key risks include [1] securing and maintaining adequate reimbursement and payer acceptance for its products, Show more. |
Qualitative Assessment
AI Analysis | Feedback
MDxHealth (MDXH) stock has lost about 80% since 3/31/2026 because of the following key factors:
1. Discontinuation of Resolve UTI Business. MDxHealth announced the discontinuation of its Resolve UTI testing offering and the closure of its Plano, Texas laboratory operations, citing an uncertain reimbursement landscape. This decision effectively eliminated a revenue stream and a growth avenue for the company, as operations at the Plano facility are expected to cease by the end of fiscal Q2 2026 (June 2026).
2. Medicare Recoupment Demand. The company disclosed a significant financial liability on April 20, 2026, when it received a Medicare contractor recoupment demand from Novitas Solutions for approximately $10.4 million related to historical Resolve testing claims. While MDxHealth is contesting this demand, the potential liability introduces considerable financial uncertainty for the company.
Show more
MDxHealth (MDXH) stock has lost about 80% since 3/31/2026 because of the following key factors:
1. Discontinuation of Resolve UTI Business. MDxHealth announced the discontinuation of its Resolve UTI testing offering and the closure of its Plano, Texas laboratory operations, citing an uncertain reimbursement landscape. This decision effectively eliminated a revenue stream and a growth avenue for the company, as operations at the Plano facility are expected to cease by the end of fiscal Q2 2026 (June 2026).
2. Medicare Recoupment Demand. The company disclosed a significant financial liability on April 20, 2026, when it received a Medicare contractor recoupment demand from Novitas Solutions for approximately $10.4 million related to historical Resolve testing claims. While MDxHealth is contesting this demand, the potential liability introduces considerable financial uncertainty for the company.
3. Wider Operating Losses and Reduced Revenue Guidance. Despite reporting Q1 2026 revenue of $27.4 million, which exceeded analyst consensus, MDxHealth's pro forma operating loss widened to $7.9 million for fiscal Q1 2026, compared to a $4.7 million loss in fiscal Q1 2025. The statutory net loss for the quarter was $8.9 million. Furthermore, the company revised its full-year fiscal 2026 revenue guidance downwards to $110-$115 million, applicable only to its core prostate cancer diagnostics business and excluding contributions from the discontinued Resolve business. This revision marked a significant reduction from the prior consensus revenue outlook of US$137.3 million.
4. Precipitous Stock Price Decline. The combination of these negative announcements led to an immediate and severe market reaction. On May 14, 2026, MDxHealth's shares plummeted approximately 41% in premarket trading and declined 49.50% by the end of the trading day. This initiated a sharp downward revaluation, contributing to the stock reaching an all-time low of $0.40 on June 28, 2026, and ultimately resulting in an approximately 80% loss in value since March 31, 2026.
Show less
Stock Movement Drivers
Fundamental Drivers
The -78.5% change in MDXH stock from 3/31/2026 to 7/8/2026 was primarily driven by a -79.2% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7082026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.30 | 0.49 | -78.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 103 | 111 | 7.7% |
| P/S Multiple | 1.1 | 0.2 | -79.2% |
| Shares Outstanding (Mil) | 50 | 52 | -4.0% |
| Cumulative Contribution | -78.5% |
Market Drivers
3/31/2026 to 7/8/2026| Return | Correlation | |
|---|---|---|
| MDXH | -78.5% | |
| Market (SPY) | 14.6% | 9.4% |
| Sector (XLV) | 10.7% | 3.9% |
Fundamental Drivers
The -86.1% change in MDXH stock from 12/31/2025 to 7/8/2026 was primarily driven by a -86.6% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7082026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.57 | 0.49 | -86.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 103 | 111 | 7.7% |
| P/S Multiple | 1.7 | 0.2 | -86.6% |
| Shares Outstanding (Mil) | 50 | 52 | -4.0% |
| Cumulative Contribution | -86.1% |
Market Drivers
12/31/2025 to 7/8/2026| Return | Correlation | |
|---|---|---|
| MDXH | -86.1% | |
| Market (SPY) | 9.6% | 18.9% |
| Sector (XLV) | 5.3% | 7.8% |
Fundamental Drivers
The -77.6% change in MDXH stock from 6/30/2025 to 7/8/2026 was primarily driven by a -79.5% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7082026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.21 | 0.49 | -77.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 95 | 111 | 17.4% |
| P/S Multiple | 1.1 | 0.2 | -79.5% |
| Shares Outstanding (Mil) | 48 | 52 | -7.1% |
| Cumulative Contribution | -77.6% |
Market Drivers
6/30/2025 to 7/8/2026| Return | Correlation | |
|---|---|---|
| MDXH | -77.6% | |
| Market (SPY) | 21.7% | 25.5% |
| Sector (XLV) | 22.0% | 9.4% |
Fundamental Drivers
The 45.6% change in MDXH stock from 6/30/2023 to 7/8/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7082026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.34 | 0.49 | 45.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 111 | 0.0% |
| P/S Multiple | � | 0.2 | 0.0% |
| Shares Outstanding (Mil) | 17 | 52 | -68.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2023 to 7/8/2026| Return | Correlation | |
|---|---|---|
| MDXH | 45.6% | |
| Market (SPY) | 74.1% | 0.7% |
| Sector (XLV) | 28.0% | -2.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MDXH Return | 3% | -100% | 3939900% | -40% | 51% | -87% | -54% |
| Peers Return | 19% | -20% | -8% | -19% | 37% | 7% | 3% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| MDXH Win Rate | 33% | 9% | 33% | 42% | 58% | 14% | |
| Peers Win Rate | 60% | 50% | 48% | 42% | 54% | 44% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| MDXH Max Drawdown | -42% | -100% | -29% | -65% | -41% | -90% | |
| Peers Max Drawdown | -29% | -44% | -49% | -37% | -37% | -43% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, TECH, ATEC, CERS, ALMR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/8/2026 (YTD)
How Low Can It Go
| Event | MDXH | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.6% | -18.8% |
| % Gain to Breakeven | 32.6% | 23.1% |
| Time to Breakeven | 31 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -13.2% | -7.8% |
| % Gain to Breakeven | 15.2% | 8.5% |
| Time to Breakeven | 9 days | 18 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -100.0% | -24.5% |
| % Gain to Breakeven | ∞% | 32.4% |
| Time to Breakeven | 30 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.8% | -33.7% |
| % Gain to Breakeven | 69.0% | 50.9% |
| Time to Breakeven | 287 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -44.3% | -19.2% |
| % Gain to Breakeven | 79.5% | 23.8% |
| Time to Breakeven | 1777 days | 105 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -19.6% | -6.8% |
| % Gain to Breakeven | 24.4% | 7.3% |
| Time to Breakeven | 307 days | 15 days |
In The Past
MDxHealth's stock fell -24.6% during the 2025 US Tariff Shock. Such a loss loss requires a 32.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MDXH | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.6% | -18.8% |
| % Gain to Breakeven | 32.6% | 23.1% |
| Time to Breakeven | 31 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -100.0% | -24.5% |
| % Gain to Breakeven | ∞% | 32.4% |
| Time to Breakeven | 30 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -40.8% | -33.7% |
| % Gain to Breakeven | 69.0% | 50.9% |
| Time to Breakeven | 287 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -44.3% | -19.2% |
| % Gain to Breakeven | 79.5% | 23.8% |
| Time to Breakeven | 1777 days | 105 days |
In The Past
MDxHealth's stock fell -24.6% during the 2025 US Tariff Shock. Such a loss loss requires a 32.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About MDxHealth (MDXH)
MDxHealth is a molecular diagnostics company dedicated to improving the diagnosis and treatment of urological cancers, primarily prostate cancer. The company develops and commercializes advanced genomic and epigenetic tests designed to provide actionable information for clinicians, helping them make more informed decisions and reduce the need for invasive procedures.
Its flagship products include SelectMDx and ConfirmMDx. SelectMDx is a non-invasive liquid biopsy (urine) test that identifies men at increased risk for high-grade prostate cancer, helping urologists determine who should undergo an initial prostate biopsy. ConfirmMDx is an epigenetic tissue test used for men with a prior negative prostate biopsy to identify those truly free of cancer, thus reducing the number of unnecessary repeat biopsies and their associated complications.
MDxHealth primarily serves urologists, oncologists, and pathologists, empowering them with precision diagnostic tools. By offering tests that differentiate between aggressive and indolent cancers, the company aims to improve patient outcomes, reduce healthcare costs, and enhance the quality of life for men facing prostate cancer concerns.
```AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
- Urology Practices and Clinics: These are the primary healthcare providers, including individual urologists and group practices, who order MDxHealth's diagnostic tests (such as SelectMDx and ConfirmMDx) for their patients.
- Hospitals and Healthcare Systems: Larger medical institutions and integrated delivery networks that include urology departments also utilize and order MDxHealth's tests.
- Healthcare Distributors: In certain international markets, MDxHealth partners with third-party distributors who then sell and facilitate the use of their diagnostic tests to local healthcare providers.
AI Analysis | Feedback
- Thermo Fisher Scientific Inc. (TMO)
- QIAGEN N.V. (QGEN)
- Roche Diagnostics GmbH (ROG)
- Promega Corporation
AI Analysis | Feedback
Michael K. McGarrity, Chief Executive Officer
Mr. McGarrity was appointed CEO in February 2019. He possesses over 25 years of experience in the healthcare industry, encompassing device, diagnostics, and biotechnology. Prior to joining MDxHealth, he served as CEO of Sterilis Medical. Before Sterilis, Mr. McGarrity was the CEO of Nanosphere (NASDAQ: NSPH), a nanotechnology-based molecular diagnostics company, where he successfully orchestrated an operational and strategic turnaround that led to its sale to Luminex (NASDAQ: LMNX) in 2016. He also spent 13 years at Stryker Corporation (NYSE: SYK) in various leadership roles within sales, marketing, and executive general management.
Scott McMahan, Interim Chief Financial Officer
Mr. McMahan assumed the role of Interim Chief Financial Officer at MDxHealth on July 30, 2025, following the resignation of the previous CFO. Prior to this, he served as the Vice President of Finance and Accounting for MDxHealth.
John Bellano, Chief Commercial Officer
Mr. Bellano joined MDxHealth in June 2019 and brings over 25 years of experience in the healthcare industry, with a focus on molecular diagnostics for the past two decades. His previous roles include Chief Commercial Officer at Sterilis, LLC, and commercial leadership positions at pharmacogenomic companies such as Assurex Health (Myriad Genetics) and AltheaDx. He has also held senior leadership roles at GenMark Diagnostics and was Vice President of Global Sales at Nanosphere.
Joseph Sollee, Executive Vice President of Corporate Development & General Counsel
Mr. Sollee has more than 20 years of experience in the healthcare industry, with senior management roles in private and publicly listed pharmaceuticals, health information technology, and molecular diagnostics companies. He has served as chief legal counsel to MDxHealth since its inception in 2003. Before MDxHealth, he led the Life Sciences Practice Group at the law firm of Kennedy Covington (now K&L Gates) and held senior legal and management positions at TherapyEdge and Triangle Pharmaceuticals. His background also includes practicing as a corporate attorney at Swidler & Berlin and as an investment banker at Smith Barney.
Kim Leroux, Executive Vice President, Revenue Cycle Management
Ms. Leroux has over 20 years of leadership experience in healthcare diagnostics, with extensive expertise in revenue cycle management, managed care, and payer relations. At MDxHealth, she is responsible for leading the strategy and execution to optimize financial performance and expand patient access to precision diagnostics.
AI Analysis | Feedback
Key Risks to MDxHealth (MDXH)
- Financial Health and Profitability: MDxHealth faces significant financial risks, characterized by poor financial strength, high debt levels, and an Altman Z-Score indicating a potential for financial instability. The company has reported ongoing net losses, with its Q4 2025 net loss increasing to $8.9 million. Concerns exist regarding its ability to achieve profitability targets, as these are not consistently reflected in most analyst models. Additionally, the company's term loan agreements contain restrictions that could limit operational flexibility, and a failure to comply with financial covenants could lead to lenders accelerating debt payments or foreclosing on assets.
- Reimbursement and Coverage for Tests: A critical risk for MDxHealth, as a diagnostics company, is the uncertainty surrounding the coverage and adequate reimbursement of its current and future tests by third-party payers, including health insurance companies. The commercial success and widespread adoption of MDxHealth's products are heavily dependent on favorable reimbursement policies and the willingness of payers to cover its services. Changes in payer claims reimbursement practices or difficulty in securing adequate coverage could materially impact the company's revenue and financial performance.
- Intense Competition and Rapid Technological Changes: The molecular diagnostics industry, in which MDxHealth operates, is highly competitive and subject to rapid technological advancements. The company faces the ongoing challenge of keeping pace with competitors and ensuring its diagnostic tests remain at the forefront of innovation. Failure to continually develop new products, maintain a competitive edge, or adapt to evolving technologies could result in a loss of market share and hinder its ability to grow and sustain its business.
AI Analysis | Feedback
AI Analysis | Feedback
MDxHealth (symbol: MDXH) operates in the precision diagnostics market, primarily focusing on urologic cancers and infections. The company has identified significant addressable markets for its main products and services, predominantly within the U.S. region.
- The aggregate total addressable market (TAM) for MDxHealth's comprehensive portfolio of precision diagnostics, which targets all stages of prostate cancer and advanced UTI detection, is estimated to be approximately $4.9 billion.
- For SelectMDx, a non-invasive liquid biopsy test for prostate cancer, the addressable market is estimated at $1.5 billion. This market size is for the U.S.
- The Genomic Prostate Score (GPS) test, used for treatment planning in prostate cancer, targets a market of $450 million.
- ResolveMDx, an advanced diagnostic tool for urinary tract infections (UTIs), addresses a U.S. market of approximately $1.0 billion, representing about 2 million tests annually.
- For MonitorMDx, a non-invasive test currently in development for active surveillance of localized prostate cancer, the estimated addressable market could be $450 million in the U.S., accounting for approximately 1.5 million men annually.
- While no specific dollar market size is provided for ConfirmMDx, it is a flagship epigenetic assay for prostate cancer detection post-biopsy.
- For AssureMDx for Bladder Cancer, launched in the United States, there are approximately 11 million patients annually referred to a urologist for hematuria, a common symptom of bladder cancer, indicating a substantial patient population for this test.
AI Analysis | Feedback
MDxHealth (MDXH) is expected to drive future revenue growth over the next 2-3 years through several key strategies and market dynamics:
- Successful Integration and Synergies from the ExoDx Acquisition: The recent acquisition of ExoDx is a significant growth catalyst. MDxHealth anticipates ExoDx to contribute more than $20 million in revenue in 2026. This integration involves cross-selling opportunities within the expanded customer base and aligning sales teams, which is expected to enhance their position in the prostate cancer diagnostic market and expand their overall diagnostic menu.
- Continued Growth in Liquid-Based Testing Volumes: MDxHealth has demonstrated substantial growth in its liquid-based test volumes, which include products like SelectMDx, ResolveMDx, and the newly acquired ExoDx. In the fourth quarter of 2025, liquid-based test volumes increased by 128% year-over-year, indicating a strong and ongoing demand for these diagnostic solutions.
- Expansion of Diagnostic Menu and Service Offerings to Urology Clients: The company emphasizes a strategy of "menu expansion" across both tissue and liquid biopsy products, which broadens their diagnostic capabilities within the prostate cancer pathway. This expansion, coupled with robust sales channels and expanded service offerings to urology clients, is credited as a key driver for sustained growth.
- Strengthening Market Position in Urology Cancer Diagnostics: MDxHealth aims to solidify its standing in the prostate cancer pathway and leverage the inherent growth of its target end markets. Specializing in molecular diagnostic tests for prostate cancer and other urologic diseases positions the company to capitalize on the increasing need for precision diagnostics in this sector.
AI Analysis | Feedback
Capital Allocation Decisions for MDxHealth (MDXH)
Share Issuance
- MDxHealth has been listed on NASDAQ since 2021, indicating share issuances related to its public listing.
- The number of outstanding shares significantly increased from 16.87 million in 2022 to 50.06 million in February 2026.
- The company issues stock options to employees, directors, and consultants.
Inbound Investments
- On February 3, 2023, MVM Partners, LLC made a significant BUY transaction in MDxHealth SA valued at $4,000,000.
- Earlier insider trading activity in January 2021 and September 2020 also showed BUY transactions.
- Institutional investors such as AWM Investment Company, Inc., MVM Partners, LLC, and others hold significant positions in MDxHealth.
Outbound Investments
- MDxHealth entered into a definitive agreement on August 5, 2025, to acquire the ExoDx business from Bio-Techne Corporation for a total consideration of $15 million.
- The acquisition involved an initial payment of $5 million in stock at closing, with an additional $2.5 million to be paid annually over the subsequent four years, split evenly between cash and cash or stock at MDxHealth's discretion.
- This acquisition, which includes the ExoDx Prostate test and a CLIA-certified clinical laboratory, was expected to close in September 2025 and is anticipated to accelerate revenue growth and be accretive to adjusted EBITDA.
Capital Expenditures
- Capital expenditures in the most recent reported quarter totaled -$0.263 million USD.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is MDxHealth Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 17.26 |
| Mkt Cap | 1.4 |
| Rev LTM | 787 |
| Op Inc LTM | -3 |
| FCF LTM | -1 |
| FCF 3Y Avg | -10 |
| CFO LTM | 52 |
| CFO 3Y Avg | -7 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 17.0% |
| Rev Chg 3Y Avg | 11.8% |
| Rev Chg Q | 12.7% |
| QoQ Delta Rev Chg LTM | 2.9% |
| Op Inc Chg LTM | 39.1% |
| Op Inc Chg 3Y Avg | 20.6% |
| Op Mgn LTM | -1.5% |
| Op Mgn 3Y Avg | -6.8% |
| QoQ Delta Op Mgn LTM | 1.4% |
| CFO/Rev LTM | 6.6% |
| CFO/Rev 3Y Avg | -4.7% |
| FCF/Rev LTM | -0.1% |
| FCF/Rev 3Y Avg | -6.5% |
Price Behavior
| Market Price | $0.49 | |
| Market Cap ($ Bil) | 0.0 | |
| Distance from 52W High | -90.1% | |
| 50 Days | 200 Days | |
| DMA Price | $1.01 | $2.92 |
| DMA Trend | down | down |
| Distance from DMA | -50.8% | -83.0% |
| 3M | 1YR | |
| Volatility | 129.4% | 84.3% |
| Downside Capture | 357.35 | 254.76 |
| Upside Capture | -342.53 | 21.97 |
| Correlation (SPY) | 8.7% | 25.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.55 | 0.28 | 1.09 | 1.35 | 1.74 | 0.30 |
| Up Beta | 4.11 | 2.45 | 2.57 | 2.22 | 2.26 | 0.43 |
| Down Beta | -1.15 | -0.77 | -0.64 | 1.22 | 1.52 | 3.88 |
| Up Capture | -305% | -360% | -174% | -90% | 14% | 8% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 6 | 12 | 22 | 43 | 105 | 280 |
| Down Capture | 290% | 386% | 388% | 234% | 178% | 51% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 15 | 29 | 40 | 81 | 140 | 335 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXH | |
|---|---|---|---|---|
| MDXH | -77.0% | 84.2% | -1.29 | - |
| Sector ETF (XLV) | 22.5% | 15.7% | 1.09 | 10.0% |
| Equity (SPY) | 21.2% | 12.5% | 1.26 | 25.3% |
| Gold (GLD) | 21.9% | 27.8% | 0.70 | 13.9% |
| Commodities (DBC) | 25.0% | 18.7% | 1.06 | -5.6% |
| Real Estate (VNQ) | 12.7% | 13.9% | 0.62 | 12.3% |
| Bitcoin (BTCUSD) | -41.4% | 42.8% | -1.13 | 17.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXH | |
|---|---|---|---|---|
| MDXH | -29.8% | 71.5% | -0.62 | - |
| Sector ETF (XLV) | 6.8% | 14.9% | 0.27 | 7.4% |
| Equity (SPY) | 13.2% | 17.1% | 0.60 | 16.5% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 10.6% |
| Commodities (DBC) | 7.8% | 19.5% | 0.30 | -1.8% |
| Real Estate (VNQ) | 2.8% | 18.9% | 0.05 | 11.4% |
| Bitcoin (BTCUSD) | 12.1% | 53.5% | 0.41 | 11.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXH | |
|---|---|---|---|---|
| MDXH | -18.6% | 75.4% | -0.63 | - |
| Sector ETF (XLV) | 10.9% | 16.6% | 0.54 | 9.6% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 18.6% |
| Gold (GLD) | 11.5% | 16.1% | 0.58 | 9.5% |
| Commodities (DBC) | 6.4% | 18.0% | 0.28 | -0.2% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 11.9% |
| Bitcoin (BTCUSD) | 58.0% | 66.2% | 0.98 | 7.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 6-K |
| 12/31/2025 | 04/03/2026 | 20-F |
| 09/30/2025 | 11/12/2025 | 6-K |
| 06/30/2025 | 08/14/2025 | 6-K |
| 03/31/2025 | 05/14/2025 | 6-K |
| 12/31/2024 | 03/31/2025 | 20-F |
| 09/30/2024 | 11/06/2024 | 6-K |
| 06/30/2024 | 08/21/2024 | 6-K |
| 03/31/2024 | 05/01/2024 | 6-K |
| 12/31/2023 | 04/30/2024 | 20-F |
| 09/30/2023 | 11/08/2023 | 6-K |
| 06/30/2023 | 08/23/2023 | 6-K |
| 03/31/2023 | 05/15/2023 | 6-K |
| 12/31/2022 | 04/25/2023 | 20-F |
| 09/30/2022 | 01/20/2023 | 6-K |
| 06/30/2022 | 08/26/2022 | 6-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/13/2026 | 6-K |
| 12/31/2025 | 04/03/2026 | 20-F |
| 09/30/2025 | 11/12/2025 | 6-K |
| 06/30/2025 | 08/14/2025 | 6-K |
| 03/31/2025 | 05/14/2025 | 6-K |
| 12/31/2024 | 03/31/2025 | 20-F |
| 09/30/2024 | 11/06/2024 | 6-K |
| 06/30/2024 | 08/21/2024 | 6-K |
| 03/31/2024 | 05/01/2024 | 6-K |
| 12/31/2023 | 04/30/2024 | 20-F |
| 09/30/2023 | 11/08/2023 | 6-K |
| 06/30/2023 | 08/23/2023 | 6-K |
| 03/31/2023 | 05/15/2023 | 6-K |
| 12/31/2022 | 04/25/2023 | 20-F |
| 09/30/2022 | 01/20/2023 | 6-K |
| 06/30/2022 | 08/26/2022 | 6-K |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.